Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brukinsa and Gazyva in relapsed/refractory follicular lymphoma
NCT03332017Phase 2Completed
- Sponsor
- BeiGene
- Start
- Nov 2017
- Primary completion
- Oct 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 17
01
Overview
A Phase 2 trial of zanubrutinib in follicular lymphoma (FL), sponsored by BeiGene. Started Nov 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03332017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332017.